Effective Induction of High-titer Antibodies by Viral Vector Vaccines

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2008 Jul 29

PMID 18660818

Citations 89

Authors

Simon J Draper

Anne C Moore

Anna L Goodman

Carole A Long

Anthony A Holder

Sarah C Gilbert

Fergal Hill

Adrian V S Hill

Affiliations

Soon will be listed here.

Abstract

Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria. Here we show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro.

Citing Articles

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.

Alharbi N, Aljamaan F, Aljami H, Alenazi M, Albalawi H, Almasoud A Vaccines (Basel). 2022; 10(8).

PMID: 36016218 PMC: 9413082. DOI: 10.3390/vaccines10081330.

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E, Ulaszewska M, Douglas A, Hill A, Spencer A Sci Rep. 2022; 12(1):14464.

PMID: 36002507 PMC: 9401198. DOI: 10.1038/s41598-022-18750-3.

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

Marsay L, Dold C, Paterson G, Yamaguchi Y, Derrick J, Chan H J Infect. 2022; 84(5):658-667.

PMID: 35245584 PMC: 7616632. DOI: 10.1016/j.jinf.2022.02.032.

BacMam virus-based surface display for HCV E2 glycoprotein induces strong cross-neutralizing antibodies and cellular immune responses in vaccinated mice.

Kord E, Roohvand F, Dubuisson J, Vausselin T, Nasr Azadani H, Keshavarz A Infect Agent Cancer. 2021; 16(1):69.

PMID: 34922563 PMC: 8684228. DOI: 10.1186/s13027-021-00407-x.

APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces -Specific Neutralizing Antibodies and T Cell Responses.

Bjerkan L, Visweswaran G, Gudjonsson A, Labbe G, Quinkert D, Pattinson D Front Immunol. 2021; 12:720550.

PMID: 34733274 PMC: 8558525. DOI: 10.3389/fimmu.2021.720550.

References

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Ogun S, Dumon-Seignovert L, Marchand J, Holder A, Hill F . The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infect Immun. 2008; 76(8):3817-23. PMC: 2493234. DOI: 10.1128/IAI.01369-07. View

Sjoberg A, Trouw L, McGrath F, Hack C, Blom A . Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol. 2006; 176(12):7612-20. DOI: 10.4049/jimmunol.176.12.7612. View

Ross T, Xu Y, Bright R, Robinson H . C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol. 2001; 1(2):127-31. PMC: 1635154. DOI: 10.1038/77802. View

Gilbert S, Schneider J, Hannan C, Hu J, Plebanski M, Sinden R . Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002; 20(7-8):1039-45. DOI: 10.1016/s0264-410x(01)00450-9. View

Wipasa J, Hirunpetcharat C, Mahakunkijcharoen Y, Xu H, Elliott S, Good M . Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J Immunol. 2002; 169(2):944-51. DOI: 10.4049/jimmunol.169.2.944. View

Genton B, Reed Z . Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis. 2007; 20(5):467-75. DOI: 10.1097/QCO.0b013e3282dd7a29. View

Hirunpetcharat C, Tian J, Kaslow D, van Rooijen N, Kumar S, Berzofsky J . Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with.... J Immunol. 1997; 159(7):3400-11. View

Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla J, Tsuji M, Nussenzweig R . Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A. 2001; 98(20):11491-6. PMC: 58757. DOI: 10.1073/pnas.191380898. View

10.

Hensmann M, Li C, Moss C, Lindo V, Greer F, Watts C . Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur J Immunol. 2004; 34(3):639-648. DOI: 10.1002/eji.200324514. View

11.

Tian J, MILLER L, Kaslow D, Ahlers J, Good M, Alling D . Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J Immunol. 1996; 157(3):1176-83. View

12.

Blom A, Villoutreix B, Dahlback B . Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?. Mol Immunol. 2004; 40(18):1333-46. DOI: 10.1016/j.molimm.2003.12.002. View

13.

Hill A . Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol. 2006; 6(1):21-32. DOI: 10.1038/nri1746. View

14.

Brodeur S, Angelini F, Bacharier L, Blom A, Mizoguchi E, Fujiwara H . C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity. 2003; 18(6):837-48. DOI: 10.1016/s1074-7613(03)00149-3. View

15.

Stevenson M, Riley E . Innate immunity to malaria. Nat Rev Immunol. 2004; 4(3):169-80. DOI: 10.1038/nri1311. View

16.

Ahlborg N, Ling I, Howard W, Holder A, Riley E . Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region. Infect Immun. 2002; 70(2):820-5. PMC: 127676. DOI: 10.1128/IAI.70.2.820-825.2002. View